Literature DB >> 32310681

Recent Advances in Insulin Therapy.

Leah M Wilson1, Jessica R Castle1.   

Abstract

Insulin therapy has advanced remarkably over the past few decades. Ultra-rapid-acting and ultra-long-acting insulin analogs are now commercially available. Many additional insulin formulations are in development. This review outlines recent advances in insulin therapy and novel therapies in development.

Entities:  

Keywords:  Basal insulin; Inhaled insulin; Insulin analog; Oral insulin; Ultra-fast acting insulin analogs

Year:  2020        PMID： 32310681     DOI： 10.1089/dia.2020.0065

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN： 1520-9156            Impact factor:   6.118


  5 in total

1.  Clinical Implementation of the Omnipod 5 Automated Insulin Delivery System: Key Considerations for Training and Onboarding People With Diabetes.

Authors:  Cari Berget; Jennifer L Sherr; Daniel J DeSalvo; Ryan S Kingman; Sheri L Stone; Sue A Brown; Alex Nguyen; Leslie Barrett; Trang T Ly; Gregory P Forlenza
Journal:  Clin Diabetes       Date:  2022-04-15

Review 2.  Current State and Principles of Basal Insulin Therapy in Type 2 Diabetes.

Authors:  Hernando Vargas-Uricoechea
Journal:  J Clin Med Res       Date:  2022-01-29

Review 3.  Polymeric microneedle-mediated sustained release systems: Design strategies and promising applications for drug delivery.

Authors:  Li Yang; Yao Yang; Hongzhong Chen; Lin Mei; Xiaowei Zeng
Journal:  Asian J Pharm Sci       Date:  2021-07-24       Impact factor: 6.598

Review 4.  Herbal tea, a novel adjuvant therapy for treating type 2 diabetes mellitus: A review.

Authors:  Xiangyuan Zhang; Lili Zhang; Boxun Zhang; Ke Liu; Jun Sun; Qingwei Li; Linhua Zhao
Journal:  Front Pharmacol       Date:  2022-09-30       Impact factor: 5.988

Review 5.  Structural principles of insulin formulation and analog design: A century of innovation.

Authors:  Mark A Jarosinski; Balamurugan Dhayalan; Yen-Shan Chen; Deepak Chatterjee; Nicolás Varas; Michael A Weiss
Journal:  Mol Metab       Date:  2021-08-21       Impact factor: 7.422
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.